|
1
|
Fink-Puches R, Zenahlik P, Bäck B, Smolle
J, Kerl H and Cerroni L: Primary cutaneous lymphomas: Applicability
of current classification schemes (European Organization for
Research and Treatment of Cancer, World Health Organization) based
on clinicopathologic features observed in a large group of
patients. Blood. 99:800–805. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kager L, Zoubek A, Pötschger U, Kastner U,
Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M,
Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation
and outcome of patients treated on neoadjuvant Cooperative
Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bacci G, Briccoli A, Rocca M, Ferrari S,
Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et
al: Neoadjuvant chemotherapy for osteosarcoma of the extremities
with metastases at presentation: Recent experience at the Rizzoli
Institute in 57 patients treated with cisplatin, doxorubicin, and a
high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas M, Lieberman J and Lal A:
Desperately seeking microRNA targets. Nat Struct Mol Biol.
17:1169–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sassen S, Miska EA and Caldas C: MicroRNA:
Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schetter AJ and Harris CC: Alterations of
microRNAs contribute to colon carcinogenesis. Semin Oncol.
38:734–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hayes CN and Chayama K: MicroRNAs as
biomarkers for liver disease and hepatocellular carcinoma. Int J
Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vanas V, Haigl B, Stockhammer V and
Sutterlüty-Fall H: MicroRNA-21 increases proliferation and
cisplatin sensitivity of osteosarcoma-derived cells. PLoS One.
11:e01610232016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan J, Chen L, Chen X, Sun W and Zhou X:
Identification of serum microRNA-21 as a biomarker for
chemosensitivity and prognosis in human osteosarcoma. J Int Med
Res. 40:2090–2097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q
and Ma B: MicroRNA-34a inhibits the proliferation and metastasis of
osteosarcoma both in vitro and in vivo. PLoS One. 7:e337782012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
He C, Xiong J, Xu X, Lu W, Liu L, Xiao D
and Wang D: Functional elucidation of miR-34 in osteosarcoma cells
and primary tumor samples. Biochem Biophys Res Commun. 388:35–40.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan Z, Choy E, Harmon D, Liu X, Susa M,
Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human
osteosarcoma and regulates cell proliferation and migration. Mol
Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gougelet A, Pissaloux D, Besse A, Perez J,
Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in
osteosarcoma as a predictive tool for ifosfamide response. Int J
Cancer. 129:680–690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song B, Wang Y, Xi Y, Kudo K, Bruheim S,
Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, et al:
Mechanism of chemoresistance mediated by miR-140 in human
osteosarcoma and colon cancer cells. Oncogene. 28:4065–4074. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haas JD, Nistala K, Petermann F, Saran N,
Chennupati V, Schmitz S, Korn T, Wedderburn LR, Förster R, Krueger
A and Prinz I: Expression of miRNAs iR-133b and miR-206 in the
II17a/f locus is co-regulated with IL-17 production in αβ and γδ T
cells. PLoS One. 6:e201712011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA
expression profile in human osteosarcoma: Role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: miR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration, and invasion
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grossi V, Peserico A, Tezil T and Simone
C: p38α MAPK pathway: A key factor in colorectal cancer therapy and
chemoresistance. World J Gastroenterol. 20:9744–9758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang G, Rong J, Zhou Z and Duo J: Novel
gene P28GANK confers multidrug resistance by modulating the
expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells. Mol Biol
(Mosk). 44:1010–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pasello M, Michelacci F, Scionti I,
Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P and Serra
M: Overcoming glutathione S-transferase P1-related cisplatin
resistance in osteosarcoma. Cancer Res. 68:6661–6668. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated
autophagy as a novel therapeutic strategy for osteosarcoma.
Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dai H, Huang Y, Li Y, Meng G, Wang Y and
Guo QN: TSSC3 overexpression associates with growth inhibition,
apoptosis induction and enhances chemotherapeutic effects in human
osteosarcoma. Carcinogenesis. 33:30–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu X, Wells A, Padilla MT, Kato K, Kim KC
and Lin Y: Asignaling pathway consisting of miR-551b, catalase and
MUC1 contributes to acquired apoptosis resistance and
chemoresistance. Carcinogenesis. 35:2457–2466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang L, Tao C, He A and He X:
Overexpression of miR-126 sensitizes osteosarcoma cells to
apoptosis induced by epigallocatechin-3-gallate. World J Surg
Oncol. 12:3832014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Y, Huang Z, Wu S, Zang X, Liu M and
Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and
promotes osteosarcoma cell resistance to cisplatin by
down-regulatin TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li
W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell
survival and cisplatin resistance through P13 K/Akt pathway in
human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen JF, Mandel EM, Thomson JM, Wu Q,
Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of
microRNA-1 and microRNA-133 in skeletal muscle proliferation and
differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen X, Wu B, Xu Z, Li S, Tan S, Liu X and
Wang K: Downregulation of miR-133b predict progression and poor
prognosis in patients with urothelial carcinoma of bladder. Cancer
Med. 5:1856–1862. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin
C and Zhang W: microRNA-133 inhibits cell proliferation, migration
and invasion in prostate cancer cells by targeting the epidermal
growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI
|
